Interchangeable Biosimilar Approval: FDA Greenl...

By João L. Carapinha

November 17, 2025

FDA Grants First Interchangeable Biosimilar Approval for HER2-Positive Breast Cancer Treatment The U.S. Food and Drug Administration (FDA...
Weight Loss: Advances in Hormone-Based Obesity Treatments
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for Ig...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications
Transforming Healthcare with the Gene Therapy Access Model
PhRMA’s Patient Access Investment: $500 Billion Commitment to Domestic ...
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals
NHS Productivity Gains at Risk: Balancing Innovation and Cost Control